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Abstract
Background: Despite mounting evidence linking both calcium and IGF1, there is a lack of
studies investigating any association between circulating levels of IGF1 and serum calcium.
Methods: Serum calcium, IGF1, and IGF-binding protein 3 (IGFBP3) were measured for 5368
participants in NHANES III. We calculated multivariable-adjusted geometric means of serum
concentrations of IGF1, IGFBP3, and IGF1/IGFBP3 by categories of calcium (lowest 5%
(!1.16 mmol/l), mid 90%, and top 5% (R1.31 mmol/l)). We also performed stratified
analyses by sex, age, ethnicity, BMI, serum levels of vitamin D, and bone mineral
density (BMD).
Results: Overall, we found that circulating calcium was positively associated with
circulating levels of IGF1 and IGFBP3, but not their molar ratio (i.e., geometric mean of
IGF1 by increasing calcium categories: 237.63, 246.51, and 264.22 ng/nl; Ptrend: 0.43;
Pfirst vs third category: 0.01). In particular, these associations were observed in women, people
aged!60, non-Hispanic whites, those with vitamin D levels above the mean, and those with
low BMD. In contrast, there was an inverse association with the molar ratio for those with
BMI R30 kg/m2.
Conclusion: We found an overall positive association between circulating levels of IGF1 and
IGFBP3 and serum calcium. However, stratification by potential effect-modifiers did not
support all suggested hypotheses. Our findings provide more insight into the interplay
between calcium and IGF1, which in the future can be investigated in larger observational
studies allowing for additional stratifications based on a combination of the different
effect-modifiers investigated here.
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Introduction
Both insulin-like growth factor 1 (IGF1) and calcium
metabolisms have been linked to chronic diseases such as
cardiovascular disease and cancer (1, 2, 3, 4). IGF1 is a
polypeptide hormone implicated in cell differentiation,
proliferation, and apoptosis. IGF1 is mainly carried in the
blood within a ternary complex with IGF-binding
protein 3 (IGFBP3). This complex stabilises IGF1 such
that its clearance is reduced and its supply to target cells is
prolonged (5, 6). Different biological mechanisms have
been suggested for the interaction between IGF1 and
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calcium metabolism. It has been shown in several
experimental studies (7, 8, 9), that IGF1 increases the
activity of 1a hydroxylase which transforms the inert
25-hydroxyvitamin D into its active form 1,25-dyhydroxy-
vitamin D. Active vitamin D is a well known regulator of
serum calcium (10). Furthermore, a recent systematic
review, based on 14 studies reporting clinical effects of
IGF1 administration, showed that IGF1 increases bone
resorption and bone formation (11), thus also suggesting a
potential interaction between calcium and IGF1 in terms
of bone metabolism (11).
Circulating levels of IGF1 have been associated with
milk and calcium intake (6, 12, 13). For instance, a study
based on 4731 men and women in the European
Prospective Investigation into Cancer and Nutrition
(EPIC) assessed the association between dietary intake
and serum concentrations of IGF1, IGFBP1, IGFBP2, and
IGFBP3 (6). They found that for each S.D. increase in total
and dairy protein and calcium intake, there was an
increase in IGF1 concentration of 2.5, 2.4, and 3.3%
respectively (P for trend: !0.001 for all) and a decrease
in IGFBP2 of 3.5, 3.5, and 5.4% respectively (P for trend:
!0.001 for all). Only calcium intake was associated with
IGFBP3 (0.8%; P!0.05), and no associations were found
for IGFBP1 (6). Despite several studies investigating a link
between dietary intake of calcium and IGF1, to our
knowledge no study has yet investigated whether
there is an association between circulating levels of IGF1
and serum calcium. Although serum calcium concen-
trations are tightly regulated, a positive association
between calcium intake and levels of ionized calcium
has been shown (14). Hence, we evaluated this relation-
ship using cross-sectional data from the Third National
Health and Nutrition Examination Survey (NHANES III), a
nationally representative sample of non-institutionalized
US Americans.
Methods
Study population
The National Center for Health Statistics (NCHS) con-
ducted NHANES III between 1988 and 1994 (15), and
designed it as a multistage stratified, clustered probability
sample of the USA civilian non-institutionalized popu-
lation who was at least 2 months old. All subjects
participated in an interview conducted at home and an
extensive physical examination, which included a blood
sample performed at a mobile examination center (15).
Study participants were randomly assigned to participate
in either the morning or afternoon/evening examination
session. We selected all men and women aged 20C years
who had serum measurements for IGF1, IGFBP3, and
calcium (nZ5368) taken during a morning examination.
Exposure measurements
Information on age, race/ethnicity, cigarette smoking,
alcohol consumption, and physical activity was collected
during the interview. Race and ethnicity were combined
into four racial/ethnic groups: non-Hispanic white,
non-Hispanic black, Mexican American, and other.
Participants were classified as never, former, and current
smokers based on the self-reported smoking habits.
Frequency of alcohol consumption was measured by a
food frequency questionnaire and categorized by times
per week. Vigorous physical activity was defined by the
following activities: jogging or running; swimming or
aerobics (for individuals 40 years or older); biking,
dancing, gardening, and calisthenics (for individuals
65 years or older); and walking and lifting weights (for
individuals 80 years and older). Participants were defined
as being diabetic when they reported a diagnosis of
diabetes or when they were using insulin or diabetic
medication. Height, weight, and waist circumference were
measured during the examination procedure. BMI was
calculated by dividing weight in kilograms by height in
meters squared (16). Serum calcium was measured using a
Hitachi 737 Analyzer (Boehringer Mannheim Diagnostics,
Indianapolis, IN, USA) (17, 18). 25-Hydroxy vitamin Dwas
measured using the Diasorin RIA Kit (Diasorin, Stillwater,
MN, USA) on frozen serum from 1994 to 1995. Coefficients
of variations (CV) from quality control samples ranged
from 13 to 19%. The RIA kit was calibrated using HPLC
purified vitamin D every 6 months. Bone mineral density
(BMD) of femur neck was measured using dual-energy
X-ray absorptiometry in 4799 participants. Low BMD was
defined as any BMD !1 S.D. below the mean of BMD in
young adults (20–29 years) (19). The Institutional Review
Board of the NCHS, Centers for Disease Control and
Prevention approved the protocols for the conduct of
NHANES III. Written informed consent was obtained from
all participants.
IGF1 and IGFBP3 measurements
IGF1 and IGFBP3 were measured by Diagnostic Systems
Laboratories (Webster, TX, USA). IGF1 concentrations were
quantified by ELISA (DSL 10-5600), which is an enzy-
matically amplified ‘one-step’ sandwich-type immunoassay.
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This procedure includes an extraction step during which
IGF1 is separated from its bindingprotein in serum. IGFBP3
concentrations were measured with an IRMA (DSL 6600).
This is a non-competitive assay in which the analyte to be
measured is ‘sandwiched’ between two antibodies.
The first anti-body is placed to the inside wall of the tube
and the other is radiolabeled for detection. A single
technician performed all procedures. Throughout the
study, samples were reanalysed if the CV for replicate
samples from a single vial was O15%. CV varied signi-
ficantly among individual QC subjects ranging from 12.3
to 17.6% for IGF1 and 8.9 to12.8% for IGFBP3 (20, 21).
Their molar ratio is defined by dividing IGF1 by IGFBP3.
Statistical analysis
All analyses were conducted with Statistical Analysis
Systems (SAS) release 9.4 (SAS Institute, Cary, NC, USA)
and SUDAAN 9.0 Software (Research Triangle Park, NC,
USA) as implemented in SAS9.2.Morning samplingweights
forNHANES IIIwereused toaccount for samplingvariability
and to adjust for differential probability of selection
of persons (15). First, we calculated the age-adjusted means
or percentages of characteristics of themen by categories of
serum calcium concentration by adjusting for the age
distribution of the USA population according to the 2000
census. Since the calcium metabolism is tightly controlled,
the following categories of calcium were chosen to capture
extreme variation: the bottom 5%, mid 90%, and top 5%.
Next, we calculated crude and adjusted geometric mean
concentrations of IGF1, IGFBP3, their molar ratio and their
95% CIs by categories of serum calcium using linear
regression. The multivariable model was adjusted for age
(continuous), sex, race/ethnicity and factors that have been
associated with IGF1 in previous studies: waist circumfer-
ence, BMI, vigorous physical activity (yes or no), serum
levels of vitamin D, cigarette smoking (never, former, and
current), alcohol intake (!2, 2–3, 4–6 times a week, or daily
or more), and history of diabetes (yes or no) (5, 6, 22). We
also adjusted for serum levels of albumin to obtain an
estimate of the free ionized calcium levels (serum
normalized calcium), which is the amount of metabolically
active serum calcium (23). In addition, we performed
stratified analyses for sex, age groups (20–39, 40–59, and
R60 years), racial/ethnic groups, obesity (!25, 25–30, and
R30 kg/m2), serum levels of vitamin D (the mean of!25.7
orR25.7 ng/ml) and BMD (normal and low) to determine
whether the results were consistent between men and
women, between younger and older people, between
different racial/ethnic groups, and between people with
different vitamin D levels. We performed a test for
interaction for all the preceding stratified analyses by
introducing an interaction term in the linear regression
models and testing its coefficient with the Wald test.
These stratificationswere chosenbased onpreviousfindings
for associations with calcium and IGF1 (5, 6, 22).
Results
Baseline characteristics of the study population by categories
of serumcalciumare shown inTable 1.Meanagewas slightly
higher for those in the extreme categories, which also
contained more women. No clear pattern by ethnicity was
observed,norwas thereadifference inwaist circumferenceby
calciumcategories.VitaminD levelswerehighest for those in
themiddle category, whereas the proportion of those with a
history of diabetes and those who were vigorously physi-
cally active was highest for those in the extreme categories.
When comparing the age, sex, and ethnicity adjusted
geometric means of the IGF biomarkers by categories of
serum normalized calcium, a statistically significant
positive association was observed for IGF1 and IGFBP3
(Table 2). These trends remained in the fully adjusted
model, but statistical significance disappeared for the
overall trend. It did, however, remain when comparing
the lowest and top 5% of the calcium categories. Neither
model showed an association between the molar ratio of
IGF1 and IGFBP3 and serum calcium levels.
When stratifying by sex, effect modification was
observed for the molar ratio (PinteractionZ0.03; Table 3).
However, for women there was a positive association
between each IGF biomarker measured and categories of
serum normalized calcium, whereas for men only a weak
positive pattern was seen for IGFBP3.
No effect modification by age categories was observed
(Table 3). However, the positive association between each
IGF biomarker measured and categories of serum
normalized calcium were slightly less pronounced for
those age 60C.
Based on the Pinteraction, effect modification by ethni-
citywas only present for IGFBP3. Therewas a positive trend
with serum calcium across ethnicity groups, but themeans
were in general higher for non-Hispanic whites than for
non-Hispanic blacks or Mexican Americans (Table 3).
An effect of BMI for the association between markers
of IGF1 and serum calcium was observed for IGF1 and the
molar ratio. In contrast to all the positive associations
observed previously, there was an inverse association
between the molar ratio and calcium for those with BMI
R30 kg/m2 (Table 3).
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No statistically significant effect modification was
observed bymedian 25-hydroxy vitamin D concentration.
However, the positive association between markers of
IGF1 and serum calcium was more pronounced for those
with vitamin D levels above the mean (Table 3).
Finally, a lack of effect modification was also seen
when stratifying by BMD. Nevertheless, a statistically
significant positive association between IGF1 markers and
serum calcium was only observed in men with normal
BMD (Table 3).
Discussion
This cross-sectional study investigated how serum levels of
calcium are correlated with circulatingmarkers of the IGF1
metabolism. Overall, we found that circulating calcium
was positively associated with circulating levels of IGF1
and IGFBP3, but not their molar ratio. These associations
were, in particular, observed in women, people aged!60,
non-Hispanic whites, those with vitamin D levels above
the median, and normal BMD. In contrast, there was
an inverse association with the molar ratio for those with
BMIR30 kg/m2.
An indirect biological association between calcium
and IGF1 has been suggested by the documented links
between IGF1 and components of bone metabolism. For
instance, vitamin D is suggested to increase circulating
IGF1 and IGFBP3, whereas IGF1 has been reported to
stimulate renal production of vitamin D, which further
modifies calcium availability and suppresses parathyroid
hormone (PTH) secretion (5). IGF1 is produced in large
amounts by osteocytes, and absence of osteocytes-derived
Table 1 Age-adjusted (standardized to the 2000 USA census age distribution) weighted characteristics by levels of serum
normalised calcium, NHANES III 1988–1991.
Serum normalized total calcium (mmol/l)
Lowest 5%,!1.16 Mid 90%, 1.16–1.31 Top 5%, R1.31
n 182 4852 324
Age (years)
Mean (S.E.M.) 47.52 (0.63) 45.91 (0.14) 46.13 (0.56)
Sex (%)
Men 38.65 47.33 39.88
Women 61.25 52.67 60.12
Race – ethnicity (%)
Non-Hispanic white 84.66 76.98 74.30
Non-Hispanic black 8.18 10.26 13.75
Mexican American 5.21 4.99 3.41
Other 1.94 7.76 8.54
Waist circumference (cm)
Mean (S.E.M.) 92.75 (1.50) 92.49 (0.38) 91.21 (1.06)
BMI (kg/m2)
Mean (S.E.M.) 26.7 (0.66) 26.77 (0.17) 26.32 (0.41)
Cigarette smoking (%)
Never 41.52 46.91 40.55
Former 30.21 25.88 34.05
Current 28.26 27.21 25.40
Alcohol intake (%)
Up to once a week 67.48 63.96 66.89
Two to three times a week 9.72 15.13 11.90
Four to six times a week 11.36 11.21 9.85
Daily or more 6.61 9.70 11.36
Vigorous physical activity (%) 11.92 9.89 11.49
Diabetes (%) 6.24 3.78 5.88
Calcium (mmol/l)
Mean (S.E.M.) 1.13 (0.003) 1.23 (0.002) 1.33 (0.003)
Vitamin D (ng/ml)
Mean (S.E.M.) 27.59 (1.06) 29.64 (0.36) 29.02 (1.18)
Femoral neck bone mineral density
(gm/cm2)
Mean (S.E.M.) 0.83 (0.01) 0.82 (0.003) 0.80 (0.01)
Albumin (g/l)
Mean (S.E.M.) 39.92 (0.48) 41.12 (0.21) 42.16 (0.25)
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IGF1 has been shown to impair bone development and
turnover (24, 25). IGF1 is observed to bind directly to
calcium channels, which opens calcium stores (26, 27).
All this evidence indicates a complex interplay between
IGF1 and calcium homeostasis as well as its regulators.
However, no study to date has investigated the association
between circulating levels of markers of IGF1 metabolism
and calcium in the population.
Epidemiological evidence for a potential link follows
from studies investigating dietary intake of calcium and
dairy products. With respect to the markers of IGF1
studied here, EPIC found a positive association between
total and dairy protein and calcium intake and IGF1 as
well as between calcium intake and IGFBP3 (6). Another
study, based on 1798 men, also showed positive associ-
ations between diary product, dairy protein, and calcium
intake and IGF1. However, they did not find any
associations with IGFBP3 (28), which is in contrast with
our findings. Overall our findings corroborate a positive
association between IGF1 and serum calcium, and
potentially also IGFBP3.
In a case–control study nested in the Physicians’
Health Study, plasma samples of IGF1 for 14 915 men was
assessed in relation to intake of low-fat milk or calcium
from dairy food (29). Despite their primary focus on
colorectal cancer, Ma et al. found that low-fat milk was
positively associated with plasma with plasma levels of
IGF1, IGFBP3, and their molar ratio, indicating a
relationship between intake of dairy products and a
modest increase in circulating IGF1 levels. Our study
assessed similar associations as in the study by Ma et al.,
but now investigating serum calcium levels, and only
observed a positive association with the molar ratio for
women, not for men. The lack of an association for men
could reflect the difference in patterns of calcium
supplement use for men and women. Women are thought
to take these supplements more frequently than men (30).
In fact, all markers studied were positively associated
with serum levels of calcium among women. This is
consistent with what was found for calcium intake. A case–
control study nested within EPIC evaluated the relation-
ship of diet with IGF1 and IGFBP3 in women. IGF1 was
positively associated with intake of milk and calcium,
however, no associations were found for IGFBP3 in this
study (31). Similar findings came from a British study
showing a 25% increase in calcium intake to be associated
with an increase in IGF1 of 5.92 ng/ml (28), which the
authors suggested follows from the high correlation
between calcium and milk in dietary surveys. A study by
Holmes et al. (13) observed an association between dietary
calcium and IGF1, but not for total calcium intake
including supplementation.
Stratification by age mainly showed positive associ-
ations for those!60 years old, which could potentially be
driven by menopausal status of women as sex-stratifica-
tion showed stronger associations for women. However,
our sample size was too small to perform a combined age
and sex stratification. It has previously been shown that
both IGF1 and calcium decrease with age in women (32),
which could potentially explain why there is a stronger
association between these markers in younger
participants.
Effect-modification by ethnicity is of interest,
especially due to the implication of race/ethnicity on
one’s susceptibility to chronic diseases such as cancer. For
instance, black men have a higher risk of getting prostate
cancer (33), and higher levels of IGF1 and lower levels of
IGFBP3 have been associated with an increased risk of
prostate cancer (34). A cross-sectional analysis based on 95
African American and 138 white males aged 33–83 years
Table 2 Geometric mean (95% CI) of IGF1 concentrations by extreme measures of calcium in a nationally representative sample in
NHANES III. All adjusted means take into account age, race/ethnicity, BMI, waist circumference, diabetes, cigarette smoking, alcohol
intake, vigorous physical activity, and serum levels of vitamin D and albumin.
Geometric mean (95% CI)
P for
trend
P for t-test
between lowest
and top 5%Lowest 5%,!1.16 Mid 90%, 1.16–1.30 Top 5%, R1.30
Age, sex, and race adjusted model
IGF1 (ng/nl) 233.83 (221.87–246.44) 246.19 (239.43–253.14) 265.55 (250.53–281.47) 0.003 0.002
IGFBP3 (mg/g) 4123.67 (3897.35–4363.14) 4345.08 (4286.72–4404.24) 4517.89 (4399.05–4639.94) 0.002 0.005
IGF1/IGFBP3 0.205 (0.19–0.22) 0.205 (0.20–0.21) 0.212 (0.20–0.22) 0.220 0.35
Fully adjusted model
IGF1 (ng/nl) 237.63 (224.28–251.77) 246.51 (239.51–253.37) 264.22 (249.28–280.06) 0.430 0.01
IGFBP3 (mg/g) 4157.63 (3947.97–4678.42) 4351.17 (4294.40–4408.69) 4521.05 (4404.72–4640.46) 0.660 0.006
IGF1/IGFBP3 0.206 (0.19–0.22) 0.205 (0.20–0.21) 0.211 (0.20–0.22) 0.70 0.56
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Table 3 Stratified geometric mean (95% CI) of IGF1 concentrations by extreme measures of calcium in a nationally representative
sample in NHANES III. All models are adjusted for age, race/ethnicity, waist circumference, diabetes, BMI, cigarette smoking, alcohol
intake, vigorous physical activity, and serum levels of vitamin D and albumin.
Geometric mean (95% CI)
P for
trend
P for
interactionLowest 5%, !1.16 Mid 90%, 1.16–1.30 Top 5%,R1.30
Stratification by sex
Men
IGF1 (ng/nl) 265.02 (244–287.48) 265.55 (258.97–272.30) 272.63 (253.41–293.30) 0.54 0.07
IGFBP3 (mg/g) 4112.56 (3882.27–4356.50) 4286.00 (4195.84–4341.40) 4394.02 (4165.09–4635.54) 0.13 0.67
IGF1/IGFBP3 0.233 (0.214–0.253) 0.225 (0.219–0.230) 0.224 (0.214–0.234) 0.43 0.03
Women
IGF1 (ng/nl) 219.14 (205.05–234.19) 230.67 (222.50–239.14) 258.04 (241.02–276.25) !0.01
IGFBP3 (mg/g) 4197.31 (3921.34–4492.71) 4425.33 (4364.17–4487.34) 4624.85 (4465.41–4789.99) 0.01
IGF1/IGFBP3 0.189 (0.172–0.207) 0.188 (0.182–0.194) 0.201 (0.191–0.213) 0.07
Stratification by age
Age 20–39
IGF1 (ng/nl) 277 (252.47–303.90) 297.29 (286.70–308.27) 325.12 (304.82–346.78) !0.01 0.06
IGFBP3 (mg/g) 4431.09 (4076.93–4816.00) 4657.81 (4588.94–4727.71) 4790.07 (4614.06–4972.79) 0.07 0.61
IGF1/IGFBP3 0.226 (0.204–0.249) 0.230 (0.223–0.238) 0.245 (0.234–0.257) 0.07 0.06
Age 40–59
IGF1 (ng/nl) 210.08 (189.95–232.35) 22.63 (215.63–229.85) 244.99 (216.95–276.64) 0.06
IGFBP3 (mg/g) 3964.98 (3643.89–4307.84) 4209.08 (4117.69–4302.50) 4468.46 (4191.88–4763.30) 0.03
IGF1/IGFBP3 0.191 (0.175–0.209) 0.191 (0.185–0.197) 0.198 (0.183–0.215) 0.42
Age R60
IGF1 (ng/nl) 186.01 (169.44–204.20) 189.65 (183.55–195.96) 189.82 (173.90–207.21) 0.80
IGFBP3 (mg/g) 3838.36 (3578.26–4117.36) 3929.23 (3857.51–4002.30) 3963.96 (3772.93–4164.67) 0.49
IGF1/IGFBP3 0.175 (0.155–0.198) 0.174 (0.169–0.179) 0.173 (0.162–0.185) 0.83
Stratification by race/ethnicity
Non-Hispanic white
IGF1 (ng/nl) 240.25 (223.93–257.77) 245.26 (237.54–253.22) 270.21 (250.96–290.93) 0.01 0.14
IGFBP3 (mg/g) 4213.72 (3962.98–4480.31) 4396.66 (4329.10–4465.27) 4642.93 (4505.76–4784.27) !0.01 0.01
IGF1/IGFBP3 0.206 (0.189–0.224) 0.201 (0.196–0.207) 0.210 (0.198–0.223) 0.45 0.86
Non-Hispanic black
IGF1 (ng/nl) 242.52 (226.76–259.39) 259.87 (253.19–266.74) 277.86 (260.76–296.07) 0.02
IGFBP3 (mg/g) 4044.04 (3759.68–4349.92) 4117.91 (4021.39–4216.73) 4424.44 (4224.45–4633.91) 0.01
IGF1/IGFBP3 0.217 (0.197–0.238) 0.228 (0.223–0.233) 0.227 (0.215–0.239) 0.66
Mexican American
IGF1 (ng/nl) 218.35 (198.24–240.50) 229.41 (221.11–238.08) 240.86 (211.42–274.39) 0.38
IGFBP3 (mg/g) 3997.00 (3801.40–4202.67) 4103.52 (4039.68–4168.37) 4430.64 (4107.00–4779.79) 0.03
IGF1/IGFBP3 0.197 (0.179–0.217) 0.202 (0.197–0.207) 0.196 (0.175–0.220) 0.91
Stratification by BMI
!25
IGF1 (ng/nl) 238.20 (215.67–263.08) 260.40 (251.32–269.80) 286.35 (262.38–312.50) !0.01 0.07
IGFBP3 (mg/g) 4345.95 (4071.36–4639.06) 4404.14 (4336.47–4472.86) 4626.24 (4485.17–4771.75) 0.05 0.61
IGF1/IGFBP3 0.198 (0.180–0.218) 0.214 (0.206–0.221) 0.224 (0.208–0.240) 0.03 0.003
25–30
IGF1 (ng/nl) 259.56 (241.69–278.76) 241.92 (233.99–250.11) 257.06 (229.98–287.33) 0.57
IGFBP3 (mg/g) 4105.16 (3758.59–4483.68) 4298.84 (4215.40–4383.93) 4440.85 (4152.11–4749.66) 0.23
IGF1/IGFBP3 0.228 (0.209–0.249) 0.203 (0.198–0.208) 0.209 (0.197–0.222) 0.76
R30
IGF1 (ng/nl) 227.74 (207.09–250.45) 227.81 (221.12–234.70) 239.25 (219.69–260.54) 0.32
IGFBP3 (mg/g) 3892.86 (3631.21–4173.37) 4321.68 (4241.96–4402.91) 4512.02 (4229.42–4813.50) 0.01
IGF1/IGFBP3 0.211 (0.196–0.228) 0.190 (0.185–0.196) 0.191 (0.179–0.205) 0.07
Stratification by vitamin D
!25.7 ng/ml
IGF1 (ng/nl) 237.03 (222.06–253.02) 232.13 (225.14–239.34) 241.92 (223.90–261.39) 0.58 0.06
IGFBP3 (mg/g) 4099.42 (3839.65–4376.76) 4229.33 (4148.06–4312.20) 4264.58 (4055.09–4484.90) 0.41 0.12
IGF1/IGFBP3 0.209 (0.195–0.223) 0.198 (0.193–0.203) 0.205 (0.192–0.218) 0.95 0.37
R25.7 ng/ml
IGF1 (ng/nl) 237.79 (215.85–261.97) 256.72 (248.31–265.42) 281.77 (265.53–299.01) !0.01
IGFBP3 (mg/g) 4186.41 (3887.46–4508.36) 4436.41 (4377.67–4495.93) 4697.57 (4567.73–4831.09) !0.01
IGF1/IGFBP3 0.205 (0.184–0.229) 0.209 (0.203–0.215) 0.217 (0.206–0.227) 0.15
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attending a prostate cancer screening clinic showed that
only in African Americans, increasing intake of calcium
and dairy servings was positively associated with IGF1
levels (34). Our results showed positive associations
between IGF1 and IGFBP3 with calcium levels in
Non-Hispanic whites and blacks, but the geometric
means of IGF1 were higher for blacks, while the geometric
means for IGFBP3 were higher for whites. Thus, our
findings for blacks corroborate with the findings by
McGreevy et al. (34), however, they did not investigate
the association between calcium and IGFBP3 by ethnicity.
Moreover, it is difficult to really make a statement about
this as we did not observe an effect in men and our sample
size was too small to make further effect modification by
both ethnicity and sex.
Positive associations between markers of IGF1 metab-
olism and calcium were mostly apparent in those with
BMI !25 kg/m2, which is interesting given the mixed
findings of both higher and lower free IGF1 concen-
trations in obese individuals (35). A recent randomised
controlled trial allocated 439 overweight or obese post-
menopausal women into exercise, dietary weight loss,
exercise and dietary weight loss, or control. Even though
there were no significant changes in either IGF1 or IGFBP3
in any of the intervention arms compared with the
control, the IGF1/IGFBP3 ratio increased significantly in
the diet and diet/exercise group compared with control
(36), whichmay be a reflection of changes in BMI. No clear
pattern for the ratio was found here in terms of BMI,
however it was positively associated with calcium in all
apart from those who were overweight.
Only amongst those with high vitamin D levels, we
observed a positive association between markers of the
IGF1 metabolism and calcium. All geometric means were
also higher among those with high vitamin D levels.
A recent review confirmed that the interplay between
vitamin D and IGF1 is complex as it occurs at both
endocrine and paracrine/autocrine levels (5). Our findings
corroborate previous biological evidence that vitamin D
increases circulating IGF1 and IGFBP3. This positive
association also support the notion that IGF1 stimulates
renal production of vitamin D, which increases calcium
availability (5).
Low IGF1 levels have been linked to bone loss and risk
of fracture (37, 38). We found a positive association
between IGF1 and IGFBP3 with calcium in those with
normal BMD of the femur neck. Additionally, levels of
IGF1 markers were markedly lower in participants with
low BMD, which corroborate prior findings (32, 39, 40).
Although no statistically significant interaction was seen,
the stronger link between IGF1 markers and calcium in
normal BMD may warrant mechanistic investigations in
the IGF1 and calcium axis in presence of bone loss.
This study has several strengths including its general-
izability following the use of nationally representative
data. Therefore it was also possible in our analysis to
perform a stratified analysis by several demographic
components. We were able to adjust for many potential
confounding factors. A limitation of this study is that we
did not have data on free ionized calcium in the NHANES
III, and remaining discrepancies may occur even though
we have corrected serum calcium based on albumin levels.
Additionally, information on other metabolites or regu-
lators of serum calcium such as PTH which may further
characterize calcium status is not available in the study.
Finally, it is worth noting that our results did not always
corroborate what has been found for the associations
between calcium intake and circulating levels of IGF1
markers. Even though a positive association has been
shown between calcium intake and ionized calcium (14),
it is possible that dietary changes are not reflected as
strongly by the tightly regulated calcium metabolism
measured in blood so that the association with IGF1
markers differs from those for dietary calcium intake.
Table 3 Continued
Geometric mean (95% CI)
P for
trend
P for
interactionLowest 5%, !1.16 Mid 90%, 1.16–1.30 Top 5%,R1.30
Stratification by BMD
Normal
IGF1 (ng/nl) 246.90 (229.90–265.16) 254.07 (246.56–261.80) 274.68 (260.26–289.89) 0.006 0.33
IGFBP3 (mg/g) 4155.13 (3900.23–4426.69) 4369.92 (4307.00–4433.76) 4533.28 (4424.43–4644.80) 0.003 0.57
IGF1/IGFBP3 0.215 (0.20–0.23) 0.210 (0.20–0.22) 0.219 (0.21–0.23) 0.30 0.37
Low
IGF1 (ng/nl) 199.28 (181.53–218.76) 192.08 (183.29–201.29) 201.60 (174.35–233.12) 0.68
IGFBP3 (mg/g) 4127.39 (3766.37–4523.01) 4064.31 (3972.17–4158.59) 4249.68 (3916.16–4611.61) 0.45
IGF1/IGFBP3 0.174 (0.16–0.20) 0.171 (0.16–0.18) 0.171 (0.16–0.19) 0.91
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Conclusion
This study showed an overall positive association between
circulating levels of IGF1 and IGFBP3 and serum calcium.
However, stratification by potential effect modifiers did not
support all suggestedhypotheses.Nevertheless, our findings
did show a stronger association between IGF1 and calcium
for those who also had higher vitamin D levels and those
with normal BMD. These cross-sectional findings provide
more insight into the interplay between calcium and IGF1,
whichmay be important in the context of diseases. This can
be investigated in larger observational studies allowing for
additional stratifications based on a combination of the
different effect modifiers investigated here.
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